Sometimes the key to making a breakthrough in research, in any field, is to look at the problem differently than anybody has ...

Proper legal structuring is essential when it comes to transferring Chinese biotech intellectual property and clinical assets ...

Fear of change is a key limiting factor that is slowing the adoption and value of AI across life sciences. It doesn't have to ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

Cuts to federal research funding at universities and research organizations are pushing academic scientists into life ...

New IRS requirements for R&D tax credits are coming into effect for tax year 2025. Life sciences companies should prepare for ...

In recent years, the classification and regulation of medical device software have become increasingly intricate, with regulatory authorities tightening pathways. This podcast delves into the nuances ...

Experts at PA Consulting offer case studies and advice for using generative AI to improve biopharma manufacturing, mitigate ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

FDA Trials And Tribulations With Connect Biopharma's Barry Quart On this week's episode of the Business of Biotech, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement ...

By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL. Chris Anzalone. It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...